A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
about
Overview of current immunotherapeutic strategies for gliomaImmunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment.Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.Controversies in the adjuvant therapy of high-grade gliomas.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human gliomaPediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.Function and mechanism of toll-like receptors in cerebral ischemic tolerance: from preconditioning to treatment.Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humansA Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With GlioblastomaPoly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury.Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant deliveryTrial Watch: Experimental Toll-like receptor agonists for cancer therapyTargeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CPoly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Prioritization schema for immunotherapy clinical trials in glioblastoma.Recent advances and future of immunotherapy for glioblastoma.Smac mimetics and innate immune stimuli synergize to promote tumor deathStimulating natural killer cells to protect against cancer: recent developments.Polypeptides and polyaminoacids in drug delivery.A novel treatment for glioblastoma: integrin inhibition.State of the art and perspectives in the treatment of glioblastoma.Vaccine adjuvant uses of poly-IC and derivatives.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Designing therapeutic cancer vaccines by mimicking viral infections.Biological Response Modifier in Cancer Immunotherapy.Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation.Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Vaccination in the immunotherapy of glioblastoma.WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.
P2860
Q26776345-FD324C8D-FAB7-4C67-A288-BDAFFE3ED3ADQ30367637-538A4E83-49B7-42B4-829C-A8CA3848C2DEQ31152190-3F68F02A-4A1D-4EB9-ADB2-4F7C2EAD38D4Q33394265-ACD0B9D3-38CE-458E-BCDC-3579A5A9D98BQ34657329-031C9017-11DC-4D51-B1A3-964C27BDE24AQ35167156-EEE5686A-2C77-42A4-940C-B9B606DBAA9FQ35575846-133BCECE-0CFC-44D4-A6ED-83B182584BC7Q35669097-4978871F-76F3-4EC7-BBDC-C3C6F59040BCQ35701142-EDA64234-E22C-4AAA-B391-BE2FB7B2FF38Q35738331-4953CF1E-AAE4-4A48-9A06-195C9A02426AQ35768825-4BF6AC3B-AE56-412B-A8D9-1866C5EFC778Q35928216-69C083DD-63D0-481F-A012-0001477A6CDEQ36194849-BCB138A3-D730-48C2-A2BD-8DF789AA821FQ36245506-29E4D936-550A-4A00-BCF0-995318D538A2Q36315857-CD41E2F3-A87D-41FF-82FE-497C40D63950Q36347457-26C1F96B-D2C2-40F0-9760-13F58CEADCD1Q36511199-7A7ACE70-E8B4-4C65-BDEA-2C37BC9692E0Q37078999-8E4F2A0E-2C1A-4EE3-BF6B-D0B0907FE6A8Q37239071-6CB3112E-EB8A-4069-978C-7455FE6F2D2BQ37270377-D1812FA4-0701-428F-A469-63C37935E229Q37877269-98F91A21-3308-44AE-BE50-71ED67C2C29AQ37975554-EA844A58-8C43-44B0-A118-015A672430E9Q37997092-F12E48F9-DB79-40BE-8764-48E1422BC575Q38233067-7F6D590D-47AC-434F-A7AF-95F9A22F5790Q38259510-BA18AE4A-8546-4468-932A-BF622FBD786BQ38657642-07431071-F6D8-4A7C-A753-7A3D1F65F2E0Q38727470-1B4B2217-25CF-4514-BC64-07308D0D2571Q38800011-25D06184-7C53-4E7F-9BBD-4C900F5D3179Q38848213-D6ABEF1A-D8FF-41C7-8591-98A1A2561745Q38867794-03ECB4C6-790C-4C4B-A2EA-2BFE38DCA476Q39142289-F6A99668-DF07-4D8C-A550-8191D93F05ADQ39196377-273D9637-D647-4066-BBA7-5FCDA63521A9Q39198219-639B5993-4448-4B4E-AF65-395D6DEBBE4AQ39236500-52830310-94F4-4CFC-BB58-941DB2E20FD4Q45073466-1689CD1C-E3EE-4BD2-B976-DB7CA38B0675Q46189367-2ED3636B-9D12-4132-80AD-9413EEDA0F8FQ47583155-1EBBB992-BA5B-4D2E-857F-A9CB57A0750BQ48222390-8A5F8F31-A152-4301-BC5A-78B3AEDE0380Q52590668-7D76A44E-1EBA-4B58-B065-ECB0532F89D6Q55257766-FAAD0CF2-F019-40F1-A804-607F425F3F55
P2860
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@ast
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@en
type
label
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@ast
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@en
prefLabel
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@ast
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
A multi-institution phase II s ...... newly diagnosed glioblastoma.
@en
P2093
Andres M Salazar
David M Peereboom
Glenn J Lesser
Marc C Chamberlain
Serena Desideri
Stuart A Grossman
Tracy T Batchelor
P2860
P304
P356
10.1093/NEUONC/NOQ071
P577
2010-07-08T00:00:00Z